Predictive and prognostic biomarkers can be an appealing strategy to stratify patients that are likely to benefit from treatment. Our non-invasive biomarkers can do exactly that, and much more. Furthermore we have a novel serum biomarker on calprotectin, which is very popular for clinical programs in inflammatory bowel diseases such as UC and Crohns. 

More about our biomarkers for IBD

Find publications

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.

We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information. This is done in order to provide the best possible experience for the visitor. Cookie policy Privacy statement